Azitra, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZTR research report →
Price Chart
About the company
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases.
- CEO
- Francisco D. Salva
- IPO
- 2023
- Employees
- 13
- HQ
- Branford, CT, US
Get TickerSpark's AI analysis on AZTR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.13M
- P/E
- -0.08
- Fwd P/E
- 0.76
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.24
- EV/EBITDA
- 0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -191.57%
- ROIC
- -265.21%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-10,966,665
- Net Income
- $-10,955,370-22.2%
- EPS
- $-22.50+85.7%
- OCF Growth
- -10.2%
- FCF Growth
- -8.0%
- 52W High
- $3.91
- 52W Low
- $0.51
- 50D MA
- $1.07
- 200D MA
- $1.68
- Beta
- -1.04
- RSI (14)
- 36
- Avg Volume
- 2.65M
No earnings-call transcripts are available for AZTR yet.
- Free Float
- 84.6%
- Shares Outstanding
- 6.06M
- Float Shares
- 5.13M
of shares held by institutions
13 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dauntless Investment Group, LLC | 12.55M | ▲ 1.26M |
| Stonepine Capital Management, LLC | 5.23M | ▼ 58.04K |
| Nantahala Capital Management, LLC | 2.21M | 0 |
| Vanguard Fiduciary Trust Co | 322.12K | ▲ 322.12K |
| Susquehanna International Group, Llp | 238.25K | ▲ 226.01K |
| Jane Street Group, LLC | 222.38K | ▼ 26.06K |
| Hrt Financial LP | 161.00K | ▲ 161.00K |
| Geode Capital Management, LLC | 95.41K | 0 |
| Stonex Group Inc. | 84.67K | ▲ 56.02K |
| Virtu Financial LLC | 67.26K | ▲ 2.32K |
| Tower Research Capital LLC (Trc) | 52.60K | ▲ 33.10K |
| Ubs Group AG | 37.85K | ▼ 12.63K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Salva Francisco D. | other | 4,064,050 |
| Jun 16, 26 | Salva Francisco D. | other | 500 |
| Apr 20, 26 | Staskey Norm | other | 35,524 |
| Apr 20, 26 | Salva Francisco D. | other | 220,879 |
| Apr 20, 26 | Whitfill Travis | other | 64,300 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 500 |
| Dec 19, 25 | Whitfill Travis | other | 23,724 |
| Dec 19, 25 | Salva Francisco D. | other | 59,309 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AZTR coverage
Recent articles, reports, and earnings notes.
No research on AZTR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AZTR report →Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
prnewswire.com · Nov 12
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models
prnewswire.com · Nov 10
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
prnewswire.com · Oct 29
Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
prnewswire.com · Oct 26
Azitra, Inc. Announces Reverse Stock Split
prnewswire.com · Oct 16
Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
prnewswire.com · Oct 1
Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short Interest
defenseworld.net · Sep 29
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.